Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) Receives Average Rating


Dallas, Texas 03/26/2014 (FINANCIALSTRENDS) – Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) has now received an average rating of “Hold” from 10 brokerages which are currently covering the company stock. Seven research-analysts have assigned a “hold” rating on Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) and 3 have assigned a “buy” rating on Rigel Pharmaceuticals, Inc (NASDAQ:RIGL). The average 12-month price-target amongst brokers who have covered the Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) stock in the past 1 year is $7.43. Separately, the Jefferies Group analysts have upped their price target on Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) shares from $6.00 up to $10.00 in the research note on 6 March and they currently have a “buy” rating on the company stock.

Rigel Pharmaceuticals (NASDAQ:RIGL) last released the company’s earnings-data on 4, March. It reported earnings per share of $0.19 for the quarter, which topped the average analysts’ projection of $0.25 by $0.06. Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) reported revenue of $5.80M for the quarter. In the same quarter of the previous year, Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) posted earnings per share of $0.30. Rigel Pharmaceuticals, Inc (NASDAQ:RIGL)’s revenue rose 57400.0% in comparison to the same quarter of the previous year. On an average, analysts project that Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) will post earnings per share of $-1.06 for the current financial year.

Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) is a clinical-stage drug-development company. It discovers & develops small-molecule-drugs to treatment inflammatory & autoimmune diseases, and muscle disorders. Rigel Pharmaceuticals, Inc (NASDAQ:RIGL)’s research focuses on the intracellular signaling pathways & related targets that are very critical to disease mechanisms. In Dec 2012, Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) initiated the Phase-1 clinical study of R348, the topical ophthalmic-JAK/SYK inhibitor, as the potential therapeutic for its chronic dry eye. In Dec 2012, AZ released its top-line results of the OSKIRA-4, the Phase 2b monotherapy-study of fostamatinib that is in development as the oral treatment for RA.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.